Securities Registration: Employee Benefit Plan (s-8)

Date : 11/13/2019 @ 10:08PM
Source : Edgar (US Regulatory)
Stock : DexCom Inc (DXCM)
Quote : 230.79  -3.62 (-1.54%) @ 12:30AM
DexCom share price Chart
After Hours
Last Trade
Last $ 230.80 ▲ 0.01 (0.00%)

Securities Registration: Employee Benefit Plan (s-8)



        
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
 
 
FORM S-8

REGISTRATION STATEMENT
Under the Securities Act of 1933
 
 
 
DexCom, Inc.
(Exact name of Registrant as Specified in Its Charter)
 
 
 
Delaware
000-51222
33-0857544
(State or other jurisdiction of
incorporation)
(Commission File Number)
(I.R.S. Employer
Identification Number)

 
6340 Sequence Drive, San Diego, CA
92121    
 
 
(Address of principal executive offices)
(Zip Code)
 

 
(858) 200-0200
 
 
(Registrant’s telephone number, including area code)
 
 
 
 
 
Amended and Restated 2015 Equity Incentive Plan
 
 
(Full Title of the Plans)
 
 
 
 
Kevin Sayer
Chairman, President and Chief Executive Officer
c/o DexCom, Inc.
6340 Sequence Drive
San Diego, California 92121
(858) 200-0200
(Name, Address and Telephone Number of Agent For Service)
 
 
 
Copies to:
Robert A. Freedman, Esq.
Michael A. Brown, Esq.
Fenwick & West LLP
801 California Street
Mountain View, CA 94041
(650) 988-8500
Patrick Murphy
General Counsel and Chief Compliance Officer
c/o DexCom, Inc.
6340 Sequence Drive
San Diego, California 92121
(858) 200-0200







 
 
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
 
 
 
 
 
 
Large accelerated Filer
 
x
 
Accelerated Filer
 
 
 
 
 
Non-accelerated Filer
 
 
Smaller reporting company
 
 
 
 
 
 
 
 
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to 7(a)(2)(b) of the Securities Act. ☐


 
 
 

 








CALCULATION OF REGISTRATION FEE  

 
Title of Each Class of
Securities to be Registered
 
Amount
to be
Registered(1)
 
Proposed
Maximum
Offering Price
Per Share
 
Proposed
Maximum
Aggregate
Offering Price
 
Amount of
Registration Fee
Common Stock, $0.001 par value
 
2,200,000(2)
 
$154.76(3)
 
$340,472,000(3)
 
$44,193
Total
 
2,200,000
 
  
 
$340,472,000
 
$44,193
 
 
(1)
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s common stock that become issuable under the Amended and Restated 2015 Equity Incentive Plan, as amended to date (the “2015 Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that increases the number of the Registrant’s outstanding shares of common stock.
(2)
Represents 2,200,000 additional shares of common reserved for issuance upon the exercise of stock options and the settlement of restricted stock unit awards under the 2015 Plan to be granted by the Registrant. Shares available for issuance under the 2015 Plan were previously registered on a Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on June 3, 2015 (File No. 333-204699) and on a Registration Statement on Form S-8 filed with the Commission on June 7, 2017 (File No. 333-218562).
(3)
Estimated pursuant to Rule 457(c) and (h) of the Securities Act, solely for purposes of calculating the registration fee, based on the average of the high and low sales price reported on the Nasdaq Global Select Market on November 6, 2019.





































 
 
 
STATEMENT PURSUANT TO GENERAL INSTRUCTION E TO FORM S-8
REGISTRATION OF ADDITIONAL SECURITIES
Pursuant to General Instruction E of Form S-8, DexCom, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register 2,200,000 additional shares of common reserved for issuance upon the exercise of stock options and the settlement of restricted stock unit awards under the 2015 Plan to be granted by the Registrant.
This registration statement (the “Registration Statement”) hereby incorporates by reference the contents of Registrant’s earlier registration statements on Form S-8 filed with the Commission on June 3, 2015 (Registration No. 333-204699) and on June 7, 2017 (Registration No. 333-218562). In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of Form S-8 has been omitted from this Registration Statement.
Item 8. Exhibits.
The following exhibits are filed herewith:

 
 
 
 
 
 
Incorporated by Reference
 
 
 
 
Exhibit
Number
 
Exhibit Document
 
Form
 
File No.
 
Date of
First Filing
 
Exhibit
Number
 
Provided
Herewith
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8-K
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8-K
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8-K
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8-K
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 




 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X
 
 
 
 
 
 
 
23.02
 
Consent of Fenwick & West LLP (included in Exhibit 5.01).
 
 
 
 
 
 
 
 
 
X
 
 
 
 
 
 
 
24.01
 
Power of Attorney (see signature page).
 
 
 
 
 
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 













 
 
 
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on this 13th day of November, 2019.
DEXCOM, INC.
 
 
By:
 
/s/ Kevin Sayer
 
 
Kevin Sayer
Chairman, President and Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints Kevin Sayer and Quentin Blackford, and each of them, his or her true and lawful attorneys-in-fact and agents with full power of substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done with respect to this Registration Statement, including post-effective amendments, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his substitute or substitutes, may lawfully do or cause to be done or by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
Signature
 
 
Capacity

 
Date
/S/    KEVIN R. SAYER
 
Chairman of the Board of Directors, President and Chief Executive Officer (Principal Executive Officer)
 
November 13, 2019
Kevin R. Sayer
 
 
 
 
 
 
/S/    QUENTIN S. BLACKFORD
 
Chief Operating Officer and Chief Financial Officer (Principal Financial and Accounting Officer)
 
November 13, 2019
Quentin S. Blackford
 
 
 
 
 
 
/S/    MARK FOLETTA
 
Lead Independent Director
 
November 13, 2019
Mark Foletta
 
 
 
 
 
 
/S/    STEVE ALTMAN
 
Director
 
November 13, 2019
Steve Altman
 
 
 
 
 
 
 
 
Director
 
 
Nicholas Augustinos
 
 
 
 
 
 
/S/    RICHARD COLLINS
 
Director
 
November 13, 2019
Richard Collins
 
 
 
 
 
 
 
 
/S/    BRIDGETTE HELLER
 
 
Director
 
November 13, 2019
Bridgette Heller
 
 
 
 
 
 
 
 
/S/    BARBARA KAHN
 
Director
 
November 13, 2019
Barbara Kahn
 
 
 
 
 
 
 
 
/S/    JAY SKYLER
 
Director
 
November 13, 2019
Jay Skyler, M.D.
 
 
 
 
 
 
 
 
/S/    ERIC TOPOL
 
Director
 
November 13, 2019
Eric Topol, M.D.
 
 
 
 
 
 
 
 
 
 
 

DexCom (NASDAQ:DXCM)
Historical Stock Chart

1 Year : From Jan 2019 to Jan 2020

Click Here for more DexCom Charts.

DexCom (NASDAQ:DXCM)
Intraday Stock Chart

Today : Tuesday 21 January 2020

Click Here for more DexCom Charts.

Latest DXCM Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200121 06:35:34